This brand name is authorized in Australia, Brazil, Hong Kong
The drug NESINA MET contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Alogliptin
UNII JHC049LO86 - ALOGLIPTIN
|
|
Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. Alogliptin improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high. |
|
2
Metformin
UNII 786Z46389E - METFORMIN HYDROCHLORIDE
|
|
Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A10BD13 | Metformin and alogliptin | A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BD Combinations of oral blood glucose lowering drugs |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: AU | Pharmaceutical Benefits Scheme | Identifier(s): 10032B, 10033C, 10035E |
| Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 501115110025205, 501115110025705, 501115110026105, 501115110026305 |
| Country: HK | Department of Health Drug Office | Identifier(s): 63195, 63196 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
